Cancer name Acute Myeloid Leukemia
Cancer Type LAML
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment TGX-221
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature MHC-I
Official Symbol NA
Mode of action PROT_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description MHC-I expression decreased following PI3K inhibitor treatment and this effect appeared to be consistent in the three types of tumor cells tested.
PMID 26883876
Title Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway